Abstract
The impact of common classes of topical antiglaucoma medications on central corneal thickness – own observations
- Department of Ophthalmology, Military Health Service Institute in Warsaw
- Department of Informatics and Telemedicine, Medical University of Warsaw
Introduction
To investigate the influence of common classes of topical antiglaucoma medications used either in monotherapy or combined therapy on CCT.
Material and methods
In a retrospective study 487 eyes from consecutive 260 patients (148 F/ 112 M) with open angle glaucoma were examined. Depending on the topical treatment they were classified into 7 groups: A/ PGA (n = 212), B/ BB (n = 54), C/ CAI (n = 36), D/ PGA + CAI (n = 25) E/ PGA + BB (n = 23) F/ BB + CAI (n = 54), G/ non-treated (n = 83). The CCT was measured using ultrasound pachymetry Tomey AL-2000. The central corneal power was measured with the Topcon keratometer. ANOVA analyses were used for statistical analysis.
Results
There were no statistically significant differences between CCT of all groups (F = 1.06, p = 0.3931); the lowest values were in the eyes treated with PGA + BB (535.9 μm SD 31.4) and the highest in the eyes treated with PGA + CAI (571.3 μm SD 46.3). The Mean CCT in group A was 550.4 μm (SD 40.8), group B 552.5 μm (SD 34.7), group C 562.6 μm (SD 40.2), group D 571.3 μm (SD 46.3), group E 535.9 μm (SD 31.4), group F 559.5 μm (SD 32.5), group F 557.5 μm (SD 42.2). There were no statistically significant differences between CCT of eyes treated with different PGA. The highest CCT was found in the eyes treated with bimatoprost (554.4 μm SD 46.0) and the lowest in the eyes treated with latanoprost (546.4 μm SD 37.7).
Conclusions
In this study CCT appears not to differ in eyes treated with different classes of antiglaucoma medications either in monotherapy or combined therapy. CCT appears not to differ in eyes treated with different prostaglandin and prostamide analogs. CCT of treated glaucoma eyes does not differ from CCT of untreated glaucoma eyes.
Keywords
glaucoma, central corneal thickness, prostaglandin analogs, matrix metalloproteinases, beta-blockers, topical carbonic anhydrase inhibitors
Integrated with